Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IT stocks not in favour today
Mon, 19 May Closing

Indian equity markets had a volatile trading session today. While the indices began the day's proceedings on a firm note, they quickly pared gains and hovered around the dotted line in the noon. However in no time, the markets gained back the momentum and closed the day on firm note. While the BSE-Sensex today closed higher by 241 points, the NSE-Nifty closed higher by 61 points. Smallcaps and Midcaps were in much demand today. The BSE Mid Cap and BSE Small Cap indices closed higher by 5.82% and 5.19% respectively. Barring stocks from IT, pharma and Consumer goods sector, all the sectoral indices closed in green.

As regards global markets, Asian indices closed mixed today while European indices have opened weak. The rupee was trading at Rs 58.55 to the dollar at the time of writing.

Amidst huge financial inflows, the rupee has advanced to Rs 58.38 per US dollar hitting 11-months high level. On the weekly basis also, the rupee posted its best weekly gains in last eight months post BJP's victory declared recently. However the rupee appreciation has negatively impacted the stock prices of IT and Pharma sector stocks. An appreciating rupee is painful for these companies, as large part their revenues come from exports. BSE IT closed down by 4.95%, while BSE healthcare was down by 3.66% today.

Do you think rupee will continue to appreciate? How will IT and pharma companies perform if the trend continues? Share your views on Equitymaster Club

Indian pharma stocks have closed the day on a weak note. IPCA Labs and Wockhardt Ltd were the leading losers today. However, Orchid Chemical was the only stock that bucked the trend and closed with healthy gains. Dr Reddy's Laboratories is likely to invest US$300 m towards its proprietary product portfolio and US$150 m towards biological segment. It also plans to increase its R&D spend to 10-11% of sales in the current fiscal from about 9.4% in the last year. Roughly 65% of the R&D spend will be on global generics while the balance 35% will be towards biological and proprietary products. An increase in R&D spend will enable the company to launch new and better products into the market and thereby increase its share.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT stocks not in favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.